The Institute has developed a biomedical cell product "Mesenchymal stem cells" and methods cell therapy of a wide range of human diseases in surgery, rheumatology, dentistry, urology, traumatology, infectology, etc. with its application. The Institute offers services for the treatment of diseases using the developed biomedical cell product under an outsourcing agreement.

The biomedical cell product (BCP) is represented by mesenchymal stem cells (MSC) of an adult with typical morphology and phenotype. The main properties of MSCs that are valuable for their clinical use are high paracrine and immunomodulatory activity, the ability to self-renewal, and multilinear differentiation potential.

The biomaterial for the production of BCP is adipose tissue containing 2–5% of native MSCs, which is 10–1000 times higher than in the corresponding fraction of adherent bone marrow cells. The active proliferation of MSCs in vitro makes it possible to obtain a cell dose sufficient for successful clinical use.

MSCs of adipose tissue has an immunomodulatory effect, suppressing the activity of almost all cells of the immune system.

MSCs are capable of induced in vitro differentiation in adipogenic, osteogenic, chondrogenic, endothelial, myogenic, and neurogenic directions, which determines the areas of clinical use of BCPs based on them. The ability of MSCs to interact with other cells, both in vitro and in vivo, through the production of paracrine factors, exerting immunomodulatory, anti-inflammatory, trophic effects and stimulating angiogenesis is of great importance for clinical efficacy.

Methods of cell therapy with the use of MSCs in the treatment of many chronic diseases have been developed, which is manifested by tissue regeneration, elimination of the inflammatory reaction, and restoration of microcirculation.

The Institute offers services for the treatment of diseases using the developed biomedical cell product "Mesenchymal stem cells" under an outsourcing agreement.

The use of MSC in clinical practice increases the effectiveness of existing treatment methods, does not cause complications and side effects.

Over the past 10 years, the Institute has carried out a number of international contracts and agreements within the framework of the Framework Programs of the European Union, as well as with leading research centers, foundations, societies:
FP7-HEALTH-2007-4.1-8 «Promotion and facilitation of international cooperation with Eastern European and Central Asian Countries» (EECAlink, Nr. 223359), 2009-2011;

UNESCO № IAP 3240246593/011/027-Minsk « Science Academies in the Central and Eastern Europe and their Role in Knowledge-based Society», 2010-2011;

FP7-PEAPLE-2012-IRSES «Development of Nanotechnology based Biosensors for Agriculture» (PIRSES-GA-2012-318520), 2012-2016;

FP7-PEAPLE-2012-IRSES «EU-Belarus-Russia Network in Nanomaterials-Driven Anti-Cancer Gene Therapy» (PIRSES-GA-2012-316730), 2013-2017;

FP7-PEOPLE-2011-IIF-299194 «Optical real-time imaging of inhibitory GABAA receptors activity using chimeric GABA channel subunit» («ImagingGABA» Nr 299194) 2013-2015;

«INNOVIMMUNE: Baltic Platform for Innovative Immunotherapies», Nr 19806/2016,2016-2018;

NAWA IAP «Strengthening and spreading international partnership activities of the Faculty of Biology and Environmental Protection for interdisciplinary research and innovation of the University of Lodz» (№ PPI/APM/2018/1/00007/U/001) 2019-2020;

H2020-MSCA-RISE-2017 «Novel 1D photonic metal oxide nanostructures for early stage cancer detection» («CanBioSe», Nr 778157) 2018-2021:

The International Organization for Neurochemistry (ISN); Takeda Science Foundation; The Karpilo-Landau Society; Swiss National Science Foundation; University of Eastern Finland; World Federation of Scientists to Support Research, etc.

Consumers interested in receiving services for the treatment of diseases using the developed biomedical cell product "Mesenchymal stem cells" within the framework of an outsourcing agreement.